Juvenile myoclonic epilepsy (JME) is a common epileptic syndrome. Before the development of the new antiepileptic drugs (AEDs) after the 1990s, Valproate (VPA) was the first-line treatment in juvenile myoclonic epilepsy. However, the frequent adverse effects and the risk for teratogenicity have resulted in a search for alternative therapies especially in women. Lamotrigine (LTG), topiramate, and levetiracetam, have been used as monotherapy or adjunctive therapy for juvenile myoclonic epilepsy in small patient series. We report a case of a thirty one-years-old female suffered from severe aggravation in myoclonic and generalized tonic-clonic (GTC) seizures after decreasing the lose of VPA and initiating LTG.
Antiepileptic drug Seizure Juvenile myoclonic epilepsy Lamotrigine
Birincil Dil | İngilizce |
---|---|
Konular | Sağlık Kurumları Yönetimi |
Bölüm | Internal Medical Sciences |
Yazarlar | |
Yayımlanma Tarihi | 31 Temmuz 2013 |
Gönderilme Tarihi | 15 Nisan 2013 |
Yayımlandığı Sayı | Yıl 2013 Cilt: 30 Sayı: 2 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.